Well I guess this Market Update would win an award for being understated !! Why the Chairman didn't quote actual dollar amounts instead of percentages or even do both is a surprise.In one sentence only Dobinson says "the share of the US testosterone market captured by Axiron continues to grow with its share of new to brand prescriptions at 25.5% and its share of total prescriptions at 7.5%". This appears to be a very strong indeed brilliant response by US doctors to the initial Eli Lilly sales effort. Perhaps someone can recall the total testosterone potential market but I believe this strong increase in prescriptions means mega millions to Acrux. Come on Chairman as you rightly point out short selling on ACR is a problem, well another ASX Announcement with dollar amounts and the percentage prescription gain on a monthly basis for Axiron will cause the shorters major problems.!!
ACR Price at posting:
$3.19 Sentiment: Buy Disclosure: Held
